Literature DB >> 16681991

Prolylcarboxypeptidase gene, chronic hypertension, and risk of preeclampsia.

Lin Wang1, Yan Feng, Yan Zhang, Huanyu Zhou, Shanqun Jiang, Tianhua Niu, Lee-Jen Wei, Xin Xu, Xiping Xu, Xiaobin Wang.   

Abstract

OBJECTIVE: Renin-angiotensin System is essential for the homeostasis of blood pressure in humans. The roles of renin-angiotensin system gene polymorphisms including angiotensinogen, angiotensin-converting enzyme, renin and angiotensin II receptor, type 1 genes in the pathogenesis of preeclampsia have been extensively studied, but most association studies produced either negative or inconsistent results. Prolylcarboxypeptidase encodes a lysosomal enzyme and is a regulator for both renin-angiotensin system and the kallikrein-kinin system. There is no published study on prolylcarboxypeptidase gene and preeclampsia. STUDY
DESIGN: We investigated the independent and joint association of five polymorphisms in angiotensinogen, angiotensin-converting enzyme, and prolylcarboxypeptidase gene and chronic hypertension with the risk of preeclampsia in 125 preeclamptic and 1040 non-preeclamptic black women enrolled at the Boston Medical Center. We used logistic regression models to estimate the odds ratios of risk for preeclampsia associated with each gene polymorphism and its joint association with chronic hypertension.
RESULTS: No association was found in four polymorphisms in angiotensinogen and angiotensin-converting enzyme. Prolylcarboxypeptidase E112D (rs2298668) D allele along and jointly with chronic hypertension were associated with a significantly increased risk of preeclampsia. Compared to women with homozygous EE genotype and without chronic hypertension, higher risks of preeclampsia were observed in DD women without chronic hypertension (OR = 3.7, 95% CI, 1.2 - 12.4) and EE women with chronic hypertension (OR = 9.1, 95% CI: 4.7 - 17.6). Women with both D allele and chronic hypertension had the highest risk (OR = 158, 95% CI, 25-infinite). This finding was validated in an independent sample of 1,015 non-black women. We further compared the prolylcarboxypeptidase transcript levels in peripheral blood cells of 23 preeclamptic (30% with chronic hypertension) and 51 non-preeclamptic (6% with chronic hypertension) women 2 - 3 days after delivery. The PRCP transcript levels were lower in ED/DD women than in EE woman (P = .03) and lower in preeclamptic women than in non-preeclamptic women (P = .007).
CONCLUSION: Our data showed that prolylcarboxypeptidase D allele coupled with chronic hypertension was associated with a significantly increased risk of preeclampsia in both black and non-black women. Gene expression assays lent further support for the functional significance of prolylcarboxypeptidase in the etiology of preeclampsia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16681991     DOI: 10.1016/j.ajog.2006.01.079

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  23 in total

1.  Influence of a novel inhibitor (UM8190) of prolylcarboxypeptidase (PRCP) on appetite and thrombosis.

Authors:  F M Rabey; R S V S Gadepalli; S Diano; Q Cheng; T Tabrizian; D Gailani; J M Rimoldi; Z Shariat-Madar
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

2.  Maternal cigarette smoking, metabolic gene polymorphisms, and preterm delivery: new insights on GxE interactions and pathogenic pathways.

Authors:  Hui-Ju Tsai; Xin Liu; Karen Mestan; Yunxian Yu; Shanchun Zhang; Yaping Fang; Colleen Pearson; Katherin Ortiz; Barry Zuckerman; Howard Bauchner; Sandra Cerda; Phillip G Stubblefield; Xiping Xu; Xiaobin Wang
Journal:  Hum Genet       Date:  2008-03-05       Impact factor: 4.132

3.  Admixture mapping of ankle-arm index: identification of a candidate locus associated with peripheral arterial disease.

Authors:  M L Scherer; M A Nalls; L Pawlikowska; E Ziv; G Mitchell; S Huntsman; D Hu; K Sutton-Tyrrell; E G Lakatta; W-C Hsueh; A B Newman; A Tandon; L Kim; P-Y Kwok; A Sung; R Li; B Psaty; A P Reiner; T Harris
Journal:  J Med Genet       Date:  2009-07-07       Impact factor: 6.318

4.  The comparative analysis of phenotypic and whole transcriptome gene expression data of ascites susceptible versus ascites resistant chickens.

Authors:  Karim Hasanpur; Mohammadreza Nassiri; Ghasem Hosseini Salekdeh
Journal:  Mol Biol Rep       Date:  2018-12-05       Impact factor: 2.316

5.  Deletion of prolyl carboxypeptidase attenuates the metabolic effects of diet-induced obesity.

Authors:  Jin Kwon Jeong; Gyorgyi Szabo; Giuseppina Mattace Raso; Rosaria Meli; Sabrina Diano
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-03-27       Impact factor: 4.310

6.  Prolylcarboxypeptidase promotes angiogenesis and vascular repair.

Authors:  Gregory N Adams; Evi X Stavrou; Chao Fang; Alona Merkulova; M Amer Alaiti; Kohsuke Nakajima; Toshifumi Morooka; Sergei Merkulov; Gretchen A Larusch; Daniel I Simon; Mukesh K Jain; Alvin H Schmaier
Journal:  Blood       Date:  2013-06-06       Impact factor: 22.113

7.  The combined association of psychosocial stress and chronic hypertension with preeclampsia.

Authors:  Yunxian Yu; Shanchun Zhang; Guoying Wang; Xiumei Hong; Eric B Mallow; Sheila O Walker; Colleen Pearson; Linda Heffner; Barry Zuckerman; Xiaobin Wang
Journal:  Am J Obstet Gynecol       Date:  2013-07-11       Impact factor: 8.661

8.  Prolyl carboxypeptidase activity decline correlates with severity and short-term outcome in acute ischemic stroke.

Authors:  Kaat Kehoe; Raf Brouns; Robert Verkerk; Sebastiaan Engelborghs; Peter Paul De Deyn; Dirk Hendriks; Ingrid De Meester
Journal:  Neurochem Res       Date:  2014-11-05       Impact factor: 3.996

9.  Association of genetic ancestry with preterm delivery and related traits among African American mothers.

Authors:  Hui-Ju Tsai; Yunxian Yu; Shanchun Zhang; Colleen Pearson; Katherin Ortiz; Xiping Xu; Howard Bauchner; Barry Zuckerman; Xiaobin Wang
Journal:  Am J Obstet Gynecol       Date:  2009-05-15       Impact factor: 8.661

10.  Prolylcarboxypeptidase (PRCP) as a new target for obesity treatment.

Authors:  B Shariat-Madar; D Kolte; A Verlangieri; Z Shariat-Madar
Journal:  Diabetes Metab Syndr Obes       Date:  2010-04       Impact factor: 3.168

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.